Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
Open accessThe DOI matches its Crossref record; 71 of the 73 references it cites were found in a registry or an index.
Abstract
Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain barrier and systemic adverse effects. Intranasal administration offers a direct route to the brain via the nasal cavity’s olfactory and trigeminal pathways. However, nasal physiology can hinder drug absorption and limit bioavailability. Therefore, the physicochemical characteristics of formulations must be optimized by means of technological strategies. Among the strategies that have been explored, lipid-based nanosystems, particularly nanostructured lipid carriers, are promising in preclinical investigations with minimal toxicity and therapeutic efficacy due to their ability to overcome challenges associated with other nanocarriers. We review the studies of nanostructured lipid carriers for intranasal administration in the treatment of ATD. Currently, no drugs for intranasal administration in ATD have marketing approval, with only three candidates, insulin, rivastigmine and APH-1105, being clinically investigated. Further studies with different candidates will eventually confirm the potential of the intranasal route of administration in the treatment of ATD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 7 Innervation of the trigeminal nerve in the nasal cavity [39].](https://figures.cochat.ai/paper-figures/fd7eb22a56924927b531540e24dc7c54/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-7.jpg)


![Figure 3 (a) Anatomy of the nasal cavity, adapted from [32]. (b) Schematic representation of the olfactory region, adapted from [33].](https://figures.cochat.ai/paper-figures/6da7e5797e14487bb33d26eefca756c0/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-3.jpg)
![Figure 4 Factors affecting absorption through the nasal route [34].](https://figures.cochat.ai/paper-figures/688df23c98974d99bc31b371dfbc1de1/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-4.jpg)
![Figure 5 Mechanisms of drug absorption across the nasal epithelium [32].](https://figures.cochat.ai/paper-figures/938fb1209c844be380aea1ff4b583526/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-5.jpg)
![Figure 6 Intranasal transport of drugs through the olfactory route to the CNS by intracellular and extracellular routes [36].](https://figures.cochat.ai/paper-figures/01baa9b26e15440b8c7d6a51c5740cd5/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-6.jpg)
![Figure 8 Schematic representation of the structure of the nasal cavity and the mechanisms of drug absorption through the nasal mucosa to the brain. (A) Direct absorption mechanism through olfactory nerve and trigeminal route. (B) Indirect absorption mechanism by systemic route [42].](https://figures.cochat.ai/paper-figures/b5c3ba1682fd4acab06b49ecce101d7b/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-8.jpg)
![Figure 9 Lipid-based nanocarriers that have been explored for drug access to the brain from the nasal route [62].](https://figures.cochat.ai/paper-figures/3b2a6127a13e497fb48f67499281c055/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-9.jpg)
![Figure 10 Main differences between solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLCs) [66].](https://figures.cochat.ai/paper-figures/9c610ddcff6e4d19aa6dd9ab70cc3c29/intranasal-drug-administration-in-alzheimer-type-dementia-towards-clinical-figure-10.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanocarriers play a crucial role in increasing drug concentrations, slowing drug release, and achieving excellent bioavailability.401,406,407”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [406]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789 · cited 2×
“There were over 50 million ATD cases globally as of 2020 [4].”
BackgroundStrategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138 · cited 1×
“The BBB is a complex structure made up of endothelial cells sealed by tight junctions, pericytes, basement membrane and astrocytes that create a continuous barrier [24].”
BackgroundBurns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859 · cited 1×
“Around 6% of adults 65 and older are affected, with women being more frequently affected than males [9].”
BackgroundCilia and Mucociliary Clearance
Bustamante-Marin, X. M., & Ostrowski, L. E. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028241 · Cited by 830 · cited 1×
“When a formulation is administered via the nose, it has to go through mucociliary clearance, which will eliminate a part of the drug and which, together with the short residence time of the drug in the nasal cavity, will limit its absorption through the mucosa [44].”
BackgroundEvaluation of intranasal delivery route of drug administration for brain targeting
Erdő, F., Bors, L. A., Farkas, D., Bajza, Á., & Gizurarson, S. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.10.009 · Cited by 744 · cited 3×
“Intranasal transport of drugs through the olfactory route to the CNS by intracellular and extracellular routes [36].”
BackgroundInfluentialGlobal, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019
Li, X., Feng, X., Sun, X., Hou, N., Han, F., & Liu, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.937486 · Cited by 703 · cited 3×
“Dementia is more common in some parts of the world than others, with a prevalence of 4.7% in Central Europe and an 8.7% prevalence in North Africa and the Middle East [5,6].”
BackgroundInfluentialAgrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630 · cited 1×
“In addition, systemic administration may present other limitations such as binding to plasma proteins, low volume of distribution, delay in drug delivery to the brain through the blood, and systemic adverse effects, especially at the gastrointestinal level (such as nausea and vomiting) [21].”
BackgroundThe discovery of Alzheimer's disease
Hippius, H., & Neundörfer, G. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/hhippius · Cited by 516 · cited 2×
“e disease is named Alzheimer’s disease in h n r of Alois Alzheimer, a German psychiatrist and pathologist, who in 1906, first describ d th case of a 50-year-old woman with pr senile dementia [10].”
BackgroundClinical translation of nanomedicines: Challenges, opportunities, and keys
Younis, M. A., Tawfeek, H. M., Abdellatif, A. A. H., Abdel-Aleem, J. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114083 · Cited by 462 · cited 1×
“Finally, the lack of widely accepted international standards for regulating nanomedicines also poses a challenge [83].”
Background
Research works printed but not linked: 1
- Rajput, 2018, Fabrication of an ion-sensitive in situ gel loaded with nanostructured lipid carrier for nose to brain delivery of donepezil, Asian J. Pharm., 12, 293
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“401,406,407 Furthermore, the combination use of appropriate cholinesterase inhibitors, such as donepezil ( 4 ) and galantamine ( 6 ), or the combination of cholinesterase inhibitors with other neurologic drugs, metal chelators, or antioxidants, may yield surprising effects in the management of…”
BackgroundHuang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Mitochondria-Targeted Delivery Strategy of Dual-Loaded Liposomes for Alzheimer’s Disease Therapy
Vasileva, L. A., Gaynanova, G. A., Valeeva, F. G., Belyaev, G. P., Zueva, I. V., Bushmeleva, K., Sibgatullina, G., Samigullin, D., Vyshtakalyuk, A. B., Petrov, K. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310494 · Cited by 51
Biomaterial strategies for regulating the neuroinflammatory response
Galindo, A. N., Rubio, D. A. F., & Hettiaratchi, M. H. (2024) · Materials Advances · doi:10.1039/d3ma00736g · Cited by 50
Peng, D., Liu, T., Lu, H., Zhang, L., Chen, H., Huang, Y., Hu, B., & Zhang, Q. (2024) · Theranostics · doi:10.7150/thno.103596 · Cited by 54
GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential
Moaket, O. S., Obaid, S. E., Obaid, F. E., Shakeeb, Y. A., Elsharief, S. M., Tania, A., Darwish, R., Butler, A. E., & Moin, A. S. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110743 · Cited by 46
Nady, D. S., Bakowsky, U., & Fahmy, S. A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105047 · Cited by 32
Polymeric nanoparticles for efficient nose-to-brain delivery
Bolon, M., Fieux, M., Monge, C., & Richard, S. (2025) · Nanoscale · doi:10.1039/d5nr00870k · Cited by 29
Sonwani, A., Pathak, A., & Jain, K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105855 · Cited by 28
Nanotechnology-driven therapies for neurodegenerative diseases: a comprehensive review
Espinosa, J. L., Park, P., Holcomb, M., Godin, B., & Villapol, S. (2024) · Therapeutic Delivery · doi:10.1080/20415990.2024.2401307 · Cited by 23
From mechanism to applications: Advanced microneedles for clinical medicine
Yang, Y., Sun, H., Sun, X. N., Wang, Y., Xu, F., Xia, W., Chen, L., Li, M., Yang, T., Qiao, Y., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.04.025 · Cited by 38
Dong, N., Ali‐Khiavi, P., Ghavamikia, N., Pakmehr, S., Sotoudegan, F., Hjazi, A. M., Gargari, M. K., Gargari, H. K., Behnamrad, P., Rajabi, M., et al. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07871-4 · Cited by 26
“Experimental medications such as APH-1105 are currently being investigated by ongoing clinical trials (NCT03806478) [12].”
Li, J., Guo, L., Cai, W., Mei, J., Liu, J., & Liu, Y. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2645830 · Cited by 22
“…researchers have developed APH-1105, a liposome-encapsulated nanomedicine that is administered intranasally and has entered phase II clinical trials (NCT03806478) to assess its safety, tolerability, and efficacy in patients with mild-to-moderate AD (Taléns-Visconti et al. 2023; ClinicalTrials.gov.”
Khan, S., Bano, N., Ahamad, S., Dar, N. J., Nazir, A., & Bhat, S. A. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216206 · Cited by 14
Phytochemical Nanoparticles for the Treatment of Neurological Disorders
Ehtezazi, T., & Sarker, S. D. (2025) · Phytochemical Analysis · doi:10.1002/pca.70020 · Cited by 13
Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Hroudová, J., & Fišar, Z. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111069 · Cited by 13
Komal, K., Ghosh, R., Sil, D., Sharma, R., Kumar, S., Pandey, P., & Kumar, M. (2025) · Inflammopharmacology · doi:10.1007/s10787-024-01636-3 · Cited by 16
“…Agency (EMA) for the treatment of AD and these medications are based on the regulation of neurotransmitters or enzymes which include the following: Donepezil, Galantamine and Rivastigmine are AchE inhibitors and Memantine is NMDA receptor antagonist (Table 2) (Taléns-Visconti et al. 2023).”
Chakraborty, S., Vishwas, S., Harish, V., Gupta, G., Paudel, K. R., Dhanasekaran, M., Goh, B. H., Zacconi, F. C. M., Pinto, T. D. J. A., Kumbhar, P., et al. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2414768 · Cited by 12
“Despite these promising potentials, there are several challenges associated with nasal drug delivery that affect the bioavailability of drugs reaching the brain [55,56].”
Sharma, G., Wadhwa, K., Kumar, S., Singh, G., & Pahwa, R. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01770-z · Cited by 13
“Indeed, transportation via the trigeminal route may occur intracellularly or paracellularly, similar to the processes observed with olfactory neurons [52].”
Zhu, T.-T., Liu, P., Hashimoto, K., & Yang, J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03603-6 · Cited by 13
Phongpradist, R., Jiaranaikulwanitch, J., Thongkorn, K., Lekawanvijit, S., Sirilun, S., Chittasupho, C., & Poomanee, W. (2023) · Gels · doi:10.3390/gels9080610 · Cited by 9
Cartas‐Cejudo, P., Cortés, A., Lachén‐Montes, M., Anaya‐Cubero, E., Puerta, E., Solas, M., Fernández‐Irigoyen, J., & Santamaría, E. (2024) · Brain Pathology · doi:10.1111/bpa.13252 · Cited by 8
“Current FDA-approved drugs such as acetylcholinesterase inhibitors, receptor antagonist, or anti-A β passive immunizations are mainly focused on neurotransmission modulation, obtaining partially increasing cognitive functions but failing in the prevention of AD progression [41, 42].”
Mazahir, F., Alam, M. I., & Yadav, A. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102318 · Cited by 10
Schindler, K. A., Torices, S., Schurhoff, N. A., Gallo, D. I., & Toborek, M. J. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115645 · Cited by 10
Gaynanova, G. A., Vasileva, L. A., Романова, Е. А., Lyubina, A. P., Belyaev, G. P., Bushmeleva, K., Zueva, I. V., Vyshtakalyuk, A. B., Voloshina, A. D., Bakhtiyarova, Y. V., et al. (2025) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2025.137695 · Cited by 8
Tutubala, T. E., Egunlusi, A. O., Fisher, D., Dube, A., & Joubert, J. (2025) · ACS Omega · doi:10.1021/acsomega.4c04887 · Cited by 12
Lavania, K., & Garg, A. (2023) · Recent Advances in Drug Delivery and Formulation · doi:10.2174/0126673878279656231204103855 · Cited by 9
Progress in nasal drug delivery research based on biomaterials
Qiu, H., Duan, X., Su, Y., Zeng, S., Zheng, D., & Liao, W. (2025) · APL Materials · doi:10.1063/5.0296863 · Cited by 5
Manzoor, S. I., Ahanger, I. A., Kamli, M. R., Malik, M. A., & Dar, T. A. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148293 · Cited by 6
Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
Panwar, A., Khan, M. I. K., Kumar, R., Kumar, R., Kumar, S., & Kumar, A. (2024) · Advances in Alzheimer s Disease · doi:10.4236/aad.2024.133006 · Cited by 5
Gungor, D., Aytekin, E., Akdağ, Y., Şahin, S., & Gülsün, T. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128321501240828054050 · Cited by 5
Cartas‐Cejudo, P., Cortés, A., Lachén‐Montes, M., Anaya‐Cubero, E., Fernández‐Irigoyen, J., & Santamaría, E. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00334 · Cited by 4
Alzheimer’s disease: unraveling role of xanthone derivatives and nanocarriers
Suhaili, I. N. A., Yow, H.-Y., Mah, S. H., Huri, H. Z., & Tan, S. L. J. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04446-8 · Cited by 4
Kariithi, B. T., Kumar, P., & Choonara, Y. E. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03386-7 · Cited by 3
“Intranasal APH-1105 represents one of the few emerging clinical candidates (NCT03806478) under investigation for Alzheimer-type dementia, reflecting growing interest in nose-to-brain delivery as a strategy to bypass the BBB [165].”
Shang, X., Chen, S.-Y., Zhang, X.-Y., Regina, I., Zhang, T., Luo, J., Yan, Y., Qiao-yuanYao, Tong, F., & Pan, L. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124468 · Cited by 2
小山, 幸., Pham, L., Murakawa, Y., Ogawa, Y., 寺内加奈子, & Davis, K. (2026) · Plants · doi:10.3390/plants15111619 · Cited by 2
Prevention of NMDA receptor sensitization by neurotoxic β-amyloid through polyphosphate coacervation
Müller, W. E. G., Perović‐Ottstadt, S., Dobmeyer, R., Neufurth, M., Nassabi, H., Muñoz‐Espí, R., Ushijima, H., Schröder, H. C., & Wang, X. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119578 · Cited by 2
Early-stage research and new pharmacological targets in Alzhei-mer's dementia
Grecu, M., Romila, A., Moldovanu, S., Condratovici-Plesa, A., Anghel, L., Oprea, V. D., & Bocancia, L. A. (2026) · Balneo and PRM Research Journal · doi:10.12680/balneo.2026.1024 · Cited by 3
Fithri, N. A., Mardiyanto, M., Fitrya, F., Rahmah, A., & Annisa, N. M. (2024) · Science & Technology Indonesia · doi:10.26554/sti.2024.9.2.284-298 · Cited by 4
Gao, H., Cheng, F., Zhang, Z., Yan, B., Liao, P., Zhang, S., Li, D., Chen, F., & Lei, P. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05320-7 · Cited by 1
“Furthermore, the experimental APH-1105 nanoparticles, a new alpha-prolactinase modulator, are currently in phase II clinical trials for AD treatment through intranasal administration [232].”
Intranasal triptolide in mice: a strategy to reduce neuroinflammation and boost cognitive function
Yan, M., Zhang, L., Zhao, J., Ge, Y., Hu, K., Zhang, Z., Zhu, X., Wu, X., Zhang, Z., & Zeng, H. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2608926 · Cited by 1
“…liposomes, for instance, exhibit good cell compatibility and low toxicity, making them suitable for achieving effective controlled release of drugs [5]. in recent years, liposome technology has gained importance in drug delivery, enhancing biodistribution, reducing toxicity, and improving…”
Development and In-Vitro Characterization of Luteolin-Loaded Nanostructured Lipid Carrier
Chavan, M. S., Pingale, R. A., & Bhairav, B. A. (2025) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3464 · Cited by 1
Séguy, L., Guyon, L., Corvaisier, S., Maurel, M., Verdié, P., Herbinet, R., Pluart, L. L., Dehouck, L., Sevin, E., Fénart, L., et al. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127181 · Cited by 1
Potential of Brain-Computer Interfaces in Dementia
Rostami, M., Mokari, N., Shariaty, F., & Gelgor, A. (2023) · International Conference on Electrical Engineering and Photonics (EExPolytech) · doi:10.1109/eexpolytech58658.2023.10318757 · Cited by 1
“As the condition progresses, individuals with dementia may struggle with performing everyday tasks, social interactions, and maintaining their personal relationships [2, 3].”
BackgroundIntranasal Delivery of Drugs to the Central Nervous System
Crowe, T. P., & Hsu, W. H. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-62604-3_6 · Cited by 2
Fatima, E., & Fatima, A. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.07.002 · Cited by 1
Cartas‐Cejudo, P., Cortés, A., Lachén‐Montes, M., Anaya‐Cubero, E., Puerta, E., Solas, M., Fernández‐Irigoyen, J., & Santamaría, E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.01.560342
The threats and therapeutics of neurodegenerative disorders: A commentary
Banik, S. P., & Bagchi, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95735-9.00034-6
Future Barriers and Possible Solutions with Recent Advances in Alzheimer’s Disease
Dwivedi, A. R., & Raghuveer, P. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_21 · Cited by 1
Kong, F., Zhang, W., Wu, T., Jingyi, D. A. I., Xu, Y. C., & Sun, T. (2025) · Chinese Journal of Analytical Chemistry · doi:10.1016/j.cjac.2025.100560
Lachén‐Montes, M., Anaya‐Cubero, E., Cartas‐Cejudo, P., Extramiana, L., Fernández‐Irigoyen, J., & Santamaría, E. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4595-6_17
An overview of intranasal drug delivery systems for Alzheimer’s disease
Unnissa, Z., Unissa, M., Hussain, M. M., & Ali, S. S. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20253380
Ujita, H., Higuchi, H., Nishioka, Y., Miyake, S., Sato, R., & Miyawaki, T. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111446
“Its advantages include its noninvasiveness, rapid drug absorption [11,12], and a pathway through the trigeminal and olfactory sensory nerve that bypasses the blood–brain barrier (BBB), enabling direct delivery to the CNS [1,13].”
Cartas‐Cejudo, P., Miguel, M. D., Romero-Murillo, S., Felizardo-Otalvaro, A. A., Extramiana, L., Fernández‐Irigoyen, J., & Santamaría, E. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.13.711520 · Cited by 1
“All these data together with experimental evidence obtained in human AD and different animal models [12,13] point out that the nasal cavity may be a useful site for early AD diagnosis [14] as well as for innovative intranasal therapies [15].”
From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials
Verma, M., & Singh, N. K. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01793-0
Kamble, V., Kolekar, K. A., Dabhole, S., Bashir, B., Kumbhar, P., Disouza, J., & Patravale, V. B. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108479
Farias, G., Chahinian, H., Hauchard, N., Brunet, D., Fantini, J., Yahi, N., Fantini, D., & Aulas, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18080987
“It also avoids the first-pass metabolism in the liver, allowing for higher bioavailability of therapeutics in the brain at low drug amounts [10,11].”
Yang, G., 孟粹达, & Zhu, D. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261486344
“22 Moreover, several studies have demonstrated that olfactory training not only improves olfactory function but may also contribute to cognitive enhancement.”
Metadata
- Authors
- Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A.
- Affiliations
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain
- Molecular Topology and Drug Design Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain
- Universitat de València (ES)
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2023-05-03
- Volume
- 15
- Issue
- 5
- Pages
- 1399
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC10223127
- OpenAlex
- W4378516181
- Cited by
- 59
- References
- 73
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 19 · 2023: 6
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- intranasal administration, Alzheimer-type dementia, nanostructured lipid carriers, lipid-based nanosystems, blood-brain barrier, intranasal drug delivery, drug bioavailability, nanocarriers, rivastigmine, insulin, Alzheimer's disease treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.